Headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee.

[2] At the beginning of the COVID-19 pandemic, CureVac was an early starter in the race to develop a German vaccine for protection against COVID-19, a disease caused by infection with the SARS-CoV-2 virus.

[3][4][5] In June 2021 the company announced that CVnCoV displayed inadequate results in Phase III clinical trials with only 47% efficacy.

CureVac has entered into various collaborations with organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, Johnson & Johnson, Genmab, the Bill & Melinda Gates Foundation, Eli Lilly and Company, GlaxoSmithKline,[9][10] Coalition for Epidemic Preparedness Innovations, the International AIDS Vaccine Initiative,[11] and the government of Germany.

[12] In 2007, Curevac received the innovation prize of the state of Baden-Württemberg[13] and was also the winner of the nationwide Weconomy competition, which is jointly awarded by the Handelsblatt newspaper and the Wissensfabrik.

[17] Later, in July 2014, CureVac signed an exclusive license agreement with Sanofi Pasteur to develop and commercialize an mRNA-based prophylactic vaccine.

[23] In February 2019, the Coalition for Epidemic Preparedness Innovations (CEPI) awarded CureVac a $34 million grant to develop its proprietary "RNA printer" prototype.

"[31] CVnCoV is an mRNA vaccine that encodes a minimal piece of the coronavirus spike protein and activates the immune system against it.

[36] In January 2021, CureVac announced a clinical development collaboration for its COVID-19 vaccine, named CVnCoV (active ingredient zorecimeran), with the multinational pharmaceutical company Bayer.

[34][35] On 12 February 2021, CureVac announced the initiation of a rolling submission with the European Medicines Agency (EMA) for their vaccine candidate, a time-optimized process for the review of all data necessary for potential market authorization.